meropenem
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
8784
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
December 13, 2025
Enhanced detection of bacterial etiologies, antibiotic resistance profile, and treatment outcomes of meningitis patients in Ethiopia: a prospective cross-sectional study.
(PubMed, BMC Microbiol)
- "PCR significantly outperformed culture in detecting bacterial pathogens. E. coli was the most common causative agent of bacterial meningitis, and we observed high rates of antibiotic resistance among Gram-negative bacteria. While most patients had favorable outcomes, low Glasgow Coma Scale scores, comorbidities, and delayed presentation to healthcare facilities were independently associated with unfavorable outcomes."
Journal • Observational data • CNS Disorders • Infectious Disease • Influenza • Pneumonia • Respiratory Diseases
December 05, 2025
Less is more: Improving outcomes in haemato-oncology with optimal antibiotic use for febrile neutropenia
(ASH 2025)
- "Management of FN: Rapid administration of piperacillin-tazobactam and amikacin (Piptaz/Ami) for fever (≥38°C) with neutropenia (≤0.5x10 9 /L or expected neutropenia) after taking BCs...Two patients had relapsed AML, 2 newly diagnosed AML (on Venetoclax/Azacytidine and one on palliative Hydroxycarbamide), and 1 post-haploidentical HSCT for lymphoma... Patient population: 49% had AML/MDS; 66% had active disease (presentation or relapse). Treatment modalities: intensive chemotherapy (37%) autologous (37%) or allogeneic HSCT (13%). Median age was 57 years (23-85)."
Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cerebral Hemorrhage • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Myelodysplastic Syndrome • Neutropenia • Pneumonia • Renal Disease
November 04, 2025
Impact of antibiotic timing on survival outcomes in CD19 and BCMA CAR-T cell therapy
(ASH 2025)
- "In particular, the PIM(piperacillin-tazobactam, imipenem, and meropenem) have been implicated with poor outcomes.This ispossibly related to dysregulation of the gut microbiome and/or impairment of hematopoietic recovery.Here, we aimed to investigate the effect of pre and post CAR-T antibiotics in patients receiving both CD19and BCMA CAR-T cell therapy. This is a single-center retrospective study of adult patients with multiple myeloma, B-celllymphoma, and acute lymphoblastic leukemia treated with autologous CD19 and BCMA targeting CAR-Tcell therapy at our center between April 2017 and August 2024. CD19 CAR-T cell products includedlisocabtagene maraleucel, tisagenlecleucel, brexucabtagene autoleucel, and axicabtagene ciloleucel.BCMA CAR-T cell products included idecabtagene vicleucel and ciltacabtagene autoleucel...Post CAR-T antibiotics were largely fourthgeneration cephalosporins such as cefepime in combination with vancomycin... Exposure to antibiotics in the 30 days..."
CAR T-Cell Therapy • Acute Lymphocytic Leukemia • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma
November 04, 2025
Pulmonary complications in acute myelogenous leukemia in post allogenic hematopoietic stem cell transplant period and yield of bronchoalveolar lavage and biopsy- single center experience
(ASH 2025)
- "Piperacillin-tazobactam was the most used empiric antibiotictherapy (36%) and then meropenem (22%). Despite low diagnostic yield, BAL did impact changes in antimicrobial modification in 1/3 ofthe cases, supporting an early role prior to extensive antimicrobial exposure. The positive predictivevalue of BAL Aspergillus galactomannan was 18% so the results should be analyzed with caution and highclinical suspicion."
Biopsy • Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Respiratory Syncytial Virus Infections • Septic Shock • Transplantation
December 12, 2025
Plazomicin: A promising novel antimicrobial in the era of bacterial resistance (Review).
(PubMed, Exp Ther Med)
- "In treating cUTIs, plazomicin has demonstrated that it is comparable to meropenem, and is a practical treatment option for outpatient antibiotic treatment settings (given intravenously, once daily, with a brief 30 min administration duration). Plazomicin is a reasonably expensive drug that should be used sparingly. In the present review, the molecular characteristics, chemical properties, mechanism of action, antibacterial spectrum, pharmacokinetics, clinical therapeutic indications, side effects, role in therapy and special considerations of plazomicin are discussed."
Journal • Review • Infectious Disease • Nephrology
December 12, 2025
β-Lactam dosing in critically ill children: predictors for target non-attainment.
(PubMed, J Antimicrob Chemother)
- "This study found an eGFR ≥90 mL/min/1.73 m2 to be associated with target non-attainment, indicating that kidney function should be taken into account when identifying individuals who may require higher dosages. These results may help identify subpopulations of paediatric patients requiring higher dosages or continuous infusion in order to achieve adequate β-lactam exposure."
Journal • Pediatrics
December 12, 2025
Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae in paediatric patients in Japan (2020-2023).
(PubMed, J Med Microbiol)
- "Overall resistance rates to penicillin (PEN), cefotaxime, meropenem (MEM) and erythromycin (ERY) were 31.8, 15.9, 18.5 and 88.7%, respectively...Genomic analysis revealed that the predominant genotypes were 15B/C-CC199, 15A-CC63, 24B-CC2754 and 10A-CC5236.Conclusion. Non-vaccine and PEN-, MEM- and ERY-resistant clones, particularly 15A-CC63 and 35B-CC558, were prevalent among paediatric pneumococci in Japan. Even with PCV20, less than half of the IPD isolates were covered; this underscores the need for ongoing genomic surveillance, antimicrobial stewardship and consideration of expanded-valency vaccines targeting additional serotypes, such as 15A and 35B."
Journal • Infectious Disease • Novel Coronavirus Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases
December 12, 2025
In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates.
(PubMed, J Antimicrob Chemother)
- "Sulbactam/durlobactam significantly increased susceptibility to oral and intravenous β-lactam antibiotics in the form of cefuroxime, cefuroxime/amoxicillin and meropenem against clinical isolates of M. abscessus. This study also found significant differences in susceptibility to β-lactam antibiotics dependent on the culture media used, highlighting that the optimal culture methods for determining MIC in M. abscessus remains uncertain. Future in vivo studies are required to determine whether the in vitro efficacy of the β-lactam combinations studied could result in clinical efficacy for M. abscessus disease."
Journal • Preclinical
December 11, 2025
Factors Associated with Candidemia After Living Donor Liver Transplantation: A Case-Control Study.
(PubMed, J Clin Med)
- " Univariate analysis revealed significant associations with prolonged intubation (p < 0.001), bile leaks (p < 0.001), relaparotomy (p < 0.001), chronic renal disease (p = 0.011), hepatocellular carcinoma (p = 0.011), and the use of antimicrobials including meropenem (p = 0.048), linezolid (p = 0.005), tigecycline (p = 0.045), third-generation cephalosporins (p = 0.003), anidulafungin (p < 0.001), fluconazole (p = 0.006), mycophenolate (p = 0.011), and total parenteral nutrition (TPN) (p = 0.049). Prolonged intubation, bile leaks, antifungal exposure, and lack of CMV prophylaxis are independently associated with higher odds of candidemia after LDLT. Targeted prophylaxis, prudent antimicrobial stewardship, and timely biliary intervention may reduce fungal morbidity and mortality in post-transplant patients."
Journal • Chronic Kidney Disease • Hepatocellular Cancer • Infectious Disease • Nephrology • Oncology • Renal Disease • Solid Tumor • Transplantation
December 11, 2025
Tricyclic boronic acids as broad-spectrum serine and metallo-β-lactamase inhibitors with in vitro activity against acinetobacter baumannii: a patent evaluation (us 2025/0223303).
(PubMed, Expert Opin Ther Pat)
- "This article concisely reviews structurally novel xeruborbactam-inspired tricyclic boronates (reported in US 2025/0223303) with promising inhibitory activities in vitro. By introducing novel thioether-based C5 sidechains onto the previously optimized bicyclic boronate core, the inventors explored novel chemical space yielding SBL/MBL inhibitors with seemingly improved activities against carbapenem-resistant (CR) Escherichia coli, Klebsiella pneumoniae, and, importantly, Acinetobacter baumannii, when used in combination with meropenem and/or biapenem (at least with respect to taniborbactam, i.e. boronate inhibitor in late-stage clinical development). Due to the major societal importance of β-lactams for modern medicine, and the clearly demonstrated clinical potential of functionalized cyclic boronates as potent dual-acting SBL/MBL inhibitors when used in combination therapies, there is ample opportunity and scope for continued investigation of this pharmacophore,..."
Journal • Preclinical • Review • Infectious Disease • Pneumonia
December 06, 2025
Susceptibilities of cefiderocol, meropenem-xeruborbactam, cefepime-taniborbactam, aztreonam-avibactam, and sulbactam-durlobactam against imipenem-non-susceptible Gram-negative bacilli in Taiwan.
(PubMed, Int J Infect Dis)
- " Cefiderocol was highly effective, whereas novel β-lactam/β-lactamase inhibitors activity varied by species and carbapenemase types. PBP3 alterations reduced FTB and AZA activity in INS-EC."
Journal • Infectious Disease • Pneumonia
December 10, 2025
Sepsis after the Altemeier procedure: A case report.
(PubMed, Medicine (Baltimore))
- "For patients with rectal prolapse who have other comorbid infections or malnutrition, thorough preoperative assessment before the Altemeier procedure is crucial for preventing severe anastomotic leakage."
Journal • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Septic Shock • CRP
December 10, 2025
Carbapenem-resistant Klebsiella pneumoniae from clinical infections: a multifactorial analysis of resistance, virulence, and biofilm potential.
(PubMed, Front Cell Infect Microbiol)
- "MIC testing showed high resistance to meropenem (71%), colistin (61%), and tigecycline (43%). These findings highlight the convergence of antimicrobial resistance, virulence factors, and biofilm-forming capacity in K. pneumoniae. The coexistence of these traits promotes persistence, increases pathogenic potential, and complicates therapeutic interventions, emphasizing the urgent need for strengthened infection control and alternative treatment strategies."
Journal • Infectious Disease • Pneumonia
December 10, 2025
Evaluation of Synergistic Effect of Colistin with Levofloxacin and Meropenem against Multidrug-resistant Acinetobacter baumannii.
(PubMed, J Res Pharm Pract)
- "However, only 40% of isolates demonstrated partial synergism with no instances of antagonistic behavior when colistin and levofloxacin were administered together. Levofloxacin and meropenem exhibit respectable synergistic effects when combined with colistin; as a result, these combinations may be clinically assessed for MDR-AB infections."
Journal • Infectious Disease
December 10, 2025
Sepsis secondary to postoperative Enterococcus gallinarum infection in a patient with rectal cancer: A case report.
(PubMed, Medicine (Baltimore))
- "The diagnosis and management of sepsis due to postoperative E gallinarum infection should focus on preventing and controlling postoperative complications, performing early etiological cultures, and selecting appropriate antibiotics."
Journal • Colorectal Cancer • Infectious Disease • Oncology • Pain • Rectal Cancer • Septic Shock • Solid Tumor
December 09, 2025
Letter to the editor: prolonged versus short-term infusion of meropenem for the treatment of sepsis: a systematic review and meta-analysis.
(PubMed, Int J Surg)
- No abstract available
Journal • Retrospective data • Infectious Disease • Septic Shock
December 09, 2025
Prolonged Meropenem Infusion in Sepsis: Targeted tool rather than universal solution - Correspondence.
(PubMed, Int J Surg)
- No abstract available
Journal • Infectious Disease • Septic Shock
December 09, 2025
Drug-Induced Liver Injury Secondary to Meropenem: Diagnostic Challenge and Therapeutic Role of Hemoadsorption.
(PubMed, Cureus)
- "Hemoadsorption may be a valuable adjunctive therapy in select cases of DILI with significant bilirubin elevation and pruritus. Clinicians should maintain a high index of suspicion for DILI in ICU patients receiving broad-spectrum antibiotics."
Journal • Cholestasis • CNS Disorders • Critical care • Dermatology • Hepatic Encephalopathy • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Liver Failure • Pneumonia • Pruritus • Respiratory Diseases
December 09, 2025
Non-O1/non-O139 Vibrio cholerae bacteremia from ingesting untreated water: A case report.
(PubMed, IDCases)
- "Targeted therapy with meropenem, based on the NOVC susceptibility profile, successfully resolved the infection. This case underscores ingestion of untreated water is a potential risk for NOVC infection. For patients with elevated inflammatory markers and positive blood cultures, it's needed to consider bacteria infection to ensure timely diagnosis and targeted therapy."
Journal • Cholera • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Pain • Pulmonary Disease
December 09, 2025
Infective Endocarditis Caused by Serratia marcescens: A Case Report and Literature Review.
(PubMed, Cureus)
- "We report the case of a middle-aged male with a significant past medical history of atrial fibrillation managed with warfarin and mitral valve replacement for rheumatic mitral stenosis. The patient was treated with a combination of intravenous meropenem and gentamicin for a total of four weeks. Follow-up TEE demonstrated complete resolution of the vegetation, and the patient had an uneventful recovery."
Journal • Atrial Fibrillation • Cardiovascular • CNS Disorders • Hypotension • Infectious Disease • Septic Shock
December 08, 2025
Case Report: Omadacycline in the Treatment of Community-Acquired Pneumonia in a Child With Multiple Antimicrobial Allergies.
(PubMed, Clin Case Rep)
- "This case report presents a 4-year-old girl with a mixed infection of CAP who exhibited hypersensitivity to multiple antimicrobial agents (piperacillin-tazobactam, ceftazidime, fosfomycin, meropenem, and levofloxacin), was treated with omadacycline followed by doxycycline, and underwent bronchoscopy with bronchoalveolar lavage. Potential adverse effects of omadacycline were evaluated, along with its utilization and dosage in children. Omadacycline has the potential to be a viable alternative anti-infective agent for the treatment of pediatric CAP in the absence of other drug options and with adequate safety evaluation and monitoring."
Journal • Allergy • Immunology • Infectious Disease • Pediatrics • Pneumonia • Respiratory Diseases
December 07, 2025
Fosfomycin-based combinations against carbapenemase-producing Klebsiella pneumoniae bloodstream infections: Correlating in vitro synergy with clinical outcomes.
(PubMed, Int J Antimicrob Agents)
- "FOF AD MIC value may have potential as a predictive marker for FOF-C treatment response in CP-Kp BSI and could aid in guiding combination therapy decisions. Larger, prospective studies using standardized synergy testing methods are needed."
Clinical data • Journal • Preclinical • Infectious Disease • Pneumonia
December 05, 2025
Evaluation of antibiotic consumption in Intensive Care Units of a teaching hospital based on defined daily dose metrics and WHO Access, Watch, Reserve classification framework.
(PubMed, J Postgrad Med)
- "The study demonstrates excessive use of 'Watch' antibiotics and a relative underuse of 'Access' agents in ICUs, emphasizing the scope for implementing robust stewardship measures including culture-guided de-escalation, formulary restriction of broad-spectrum agents, and implementing stringent surgical prophylaxis protocols."
Journal • Critical care
December 05, 2025
Pathogen distribution, antimicrobial resistance and attributable cost analysis of neonatal sepsis in neonatal intensive care units: a propensity score matching study.
(PubMed, Front Pediatr)
- "Antimicrobial resistance analysis revealed high resistance rates of Gram-positive bacteria to penicillin G (94.6%) and oxacillin (89.3%). Gram-negative pathogens exhibited high resistance to levofloxacin (75.0%), ceftriaxone (66.7%), cefepime (66.7%), and meropenem (58.3%)...NS significantly increases the hospitalization resource consumption in NICUs. This study provides key evidence for optimizing antibiotic use strategies and advancing precision healthcare payment reform, and calls for integrating resistance surveillance with cost-control measures to reduce the health economic impact of NS."
HEOR • Journal • Critical care • Infectious Disease • Septic Shock
December 05, 2025
Neutrophils, not macrophages, aid phage-mediated control of pulmonary Pseudomonas aeruginosa infection.
(PubMed, Front Immunol)
- "Previously, we demonstrated that a two-phage cocktail exhibited low immunogenicity in mice and, when combined with meropenem, significantly improved clearance of ventilator-associated Pseudomonas aeruginosa pneumonia, reduced inflammation, and disrupted biofilms more effectively than either treatment alone...Alveolar macrophages, however, do not significantly contribute to infection resolution in vivo. Since neutrophils play a key-role in supporting phage-mediated Pseudomonas clearance, the efficacy of phage therapy is closely linked to the hosts immune competence - an important consideration when treating immunocompromised patients."
Journal • Infectious Disease • Inflammation • Pneumonia • Respiratory Diseases
1 to 25
Of
8784
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352